About the Journal .................................................................................. 1
Article Type Specifications .................................................................. 2
Preparation of Articles .......................................................................... 3
How to Submit ....................................................................................... 5
Post-Acceptance ..................................................................................... 5
Costs ........................................................................................................ 6
Editorial Policies ................................................................................... 6
Further Information ............................................................................ 10

ABOUT THE JOURNAL

Aims and Scope
Nutrition & Diabetes is a peer-reviewed, open access online journal publishing clinical, metabolic, genetic and epidemiological studies that describe methodologies, mechanisms, and associations in relation to diabetes and nutrition related diseases. The journal will also publish papers concerned with the benefits of nutrition and lifestyle interventions and therapeutic trials in diabetes or related diseases for both clinical disease management and health promotion. Contributions of broad biological interest and impact are especially encouraged. Topics of particular interest within the journal’s scope include those listed below:

Basic science
- molecular biology of adipose tissue, muscle and liver
- molecular basis of macronutrient metabolism and inflammation
- genetics - tissue gene expression; genotypes, SNPs and phenotypic variability
- epigenetics

Experimental medicine
- food intake regulation
- fat, carbohydrate and energy metabolism
- body composition with focus on the assessment of individual fat depots and ectopic fat
- animal models of overweight and nutrition-related diseases

Metabolic Syndrome
- aetiological factors
- ethnic differences
- relationship with disease outcomes
- novel therapies

Dietary interventions
- reduction of cardiovascular disease risk factors
- reduction in overweight and its metabolic sequelae
- randomised controlled trials of dietary/lifestyle interventions in diabetes
- randomised, controlled trials of major dietary intervention studies e.g. fruit and vegetable/whole grains, Mediterranean diet studies on health risks
- use of functional food in prevention and treatment of NCDs
- personalized nutrition

Epidemiology
- prospective cohort studies of links between nutrition and lifestyle on NCDs
- population studies of associations between nutritional factors and NCDs, with particular emphasis on regional/international variations
- longitudinal studies addressing critical life periods and their long-term effect on NCDs

Journal Details
Founding Editor-in-Chief:
Richard L. Atkinson, M.D., Director, Obetech Obesity Research Center, Virginia Biotechnology Research Park, Richmond, USA

Editorial office:
Nature Publishing Group, The Macmillan Building, 4 Crinan Street, London UK
nutd@nature.com

Impact factor: 3.534 (2015 Journal Citation Reports, Thomson Reuters, 2016).
<table>
<thead>
<tr>
<th>ARTICLE DESCRIPTION</th>
<th>ABSTRACT AND KEYWORDS</th>
<th>WORD LIMIT</th>
<th>TABLES/FIGURES</th>
<th>REFERENCES</th>
</tr>
</thead>
</table>
| Articles            | Structured abstract:  
• Background/Objectives  
• Subjects/Methods  
• Results  
• Conclusions | Abstract: 300 words  
Article: 4,000 words max excluding abstract, references, figures and tables. | Max of 6  
Max of 60. |
| Brief Communications | Unstructured abstract | Abstract: 200 words  
Article: 1,500 words max excluding abstract, references, figures and tables. | Max of 2  
Max of 20 |
| Review Articles     | Unstructured abstract | Abstract: 200 words  
Article: 7,500 words max excluding abstract, references, figures and tables. | Max of 8  
Max of 120 |
| Mini-Reviews        | Unstructured abstract | Abstract: 150 words  
Article: 3,000 words max excluding abstract, references, figures and tables. | Max of 6  
Max of 50 |
| Correspondences     | No abstract required. | 500 words max excluding references, figures and tables. | Max of 2  
Max of 10 |
| Editorials (by Editor invitation only) | No abstract required. | 1,000 words excluding references, figures and tables. | Max of 2  
Max of 10 |
| Technical Reports   | Structured abstract | Abstract: 300 words  
Article: 2,500 words excluding references, figures and tables. | Max of 4  
Max of 25 |
Please note that articles must contain the following components. Please see below for further details.

- Cover letter
- Title page (excluding acknowledgements)
- Abstract
- Introduction
- Materials (or Subjects) and Methods
- Results
- Discussion
- Acknowledgements
- Conflict of Interest
- References
- Figure legends
- Tables
- Figures

**Cover Letter:** The uploaded covering letter must state the material is original research, has not been previously published and has not been submitted for publication elsewhere while under consideration. If the manuscript has been previously considered for publication in another journal, please include the previous reviewer comments, to help expedite the decision by the Editorial team. Add note about including conflict of interest statement.

**Title Page:** The title page should bear the title of the paper, the full names of all the authors and their affiliations, together with the name, full postal address, telephone and fax numbers and e-mail address of the author to whom correspondence and offprint requests are to be sent (this information is also asked for on the electronic submission form). The title page must also contain a Conflict of Interest statement (see Editorial Policy section).

- The title should be brief, informative, of 150 characters or less and should not make a statement or conclusion.
- The running title should consist of no more than 50 letters and spaces. It should be as brief as possible, convey the essential message of the paper and contain no abbreviations.
- Authors should disclose the sources of any support for the work, received in the form of grants and/or equipment and drugs.
- If authors regard it as essential to indicate that two or more co-authors are equal in status, they may be identified by an asterisk symbol with the caption ‘These authors contributed equally to this work’ immediately under the address list.

**Abstract:** Articles must be prepared with a structured abstract designed to summarise the essential features of the paper in a logical and concise sequence under the following mandatory headings:

- **Background/Objectives:** What was the main question or hypothesis tested?
- **Subjects/Methods:** How many subjects were recruited, how many dropped out? Was the study randomised, case-controlled etc? Interventions/methods used and duration of administration.
- **Results:** Indicate 95% confidence intervals and exact P value for effects.
- **Conclusions:** Answer (significant or not) to main question.

**Introduction:** The Introduction should assume that the reader is knowledgeable in the field and should therefore be as brief as possible but can include a short historical review where desirable.

**Materials/Subjects and Methods:** This section should contain sufficient detail, so that all experimental procedures can be reproduced, and include references. Methods, however, that have been published in detail elsewhere should not be described in detail. Authors should provide the name of the manufacturer and their location for any specifically named medical equipment and instruments, and all drugs should be identified by their pharmaceutical names, and by their trade name if relevant.

**Results and Discussion:** The Results section should briefly present the experimental data in text, tables or figures. Tables and figures should not be described extensively in the text, either. The discussion should focus on the interpretation and the significance of the findings with concise objective comments that describe their relation to other work in the area. It should not repeat information in the results. The final paragraph should highlight the main conclusion(s), and provide some indication of the direction future research should take.

**Acknowledgements:** These should be brief, and should include sources of support including sponsorship (e.g. university, charity, commercial organisation) and sources of material (e.g. novel drugs) not available commercially.

**Conflict of Interest:** Authors must declare whether or not there are any competing financial interests in relation to the work described. This information must be included at this stage and will be published as part of the paper. Conflict of interest should be noted in the cover letter and also on the title page. Please see the Conflict of Interest documentation in the Editorial Policy section for detailed information.

**References:** Only papers directly related to the article should be cited. Exhaustive lists should be avoided. References should follow the Vancouver format. In the text they should appear as numbers starting at one and at the end of the paper they should be listed (double-spaced) in numerical order corresponding to the order of citation in the text. Where a reference is to appear next to a number in the text, for example following an equation, chemical formula or biological acronym, citations should be written as (ref. X) and not as superscript.

Example. “detectable levels of endogenous Bcl-2 (ref. 3), as confirmed by western blot”

All authors should be listed for papers with up to six authors; for papers with more than six authors, the first six only should be listed, followed by et al. Abbreviations for titles of medical periodicals should conform to those used in the latest edition of Index Medicus. The first and last page numbers for each reference should be provided. Abstracts and letters must be identified as such. Papers in press may be included in the list of references.

Personal communications must be allocated a number and included in the list of references in the usual way or simply referred to in the text; the authors may choose which method to use. In either case authors must obtain permission from the individual concerned to quote his/her unpublished work.

Examples:

- Journal article, up to six authors:
Language Editing

Authors who are not native speakers of English sometimes receive negative comments from referees or editors about the language and grammar usage in their manuscripts, which can contribute to a paper being rejected. To reduce the possibility of such problems, we strongly encourage such authors to take at least one of the following steps:

- Have your manuscript reviewed for clarity by a colleague whose native language is English.
- Review the tips for technical writing here: [http://www.nature.com/authors/author_resources/how_write.html](http://www.nature.com/authors/author_resources/how_write.html).
- Use an English language editing service such as Nature Publishing Group Language Editing. An editor will improve the English to ensure that your meaning is clear and to identify problems that require your review.

Please note that the use of a language editing service is at the author's own expense and does not guarantee that the article will be selected for peer review or accepted.

HOW TO SUBMIT

Pre-submission Enquiries

Pre-submission enquiries should be submitted via the online submission system. All other pre-submission enquiries should be directed to the editorial office:
Email: nutd@nature.com

Online Submission

We only accept manuscript submission via our [online manuscript submission system](http://www.nature.com). Before submitting a manuscript, authors are encouraged to consult both our [Editorial Policies](http://www.nature.com) and the [Submission Instructions](http://www.nature.com) for our online manuscript submission system. If you have not already done so, please [register for an account](http://www.nature.com) with our online manuscript system. You will be able to monitor the status of your manuscript online throughout the editorial process.

Submission of Revisions

Authors submitting a revised manuscript after review are asked to include the following:

1. A rebuttal letter, indicating point-by-point how you have addressed the comments raised by the reviewers. If you disagree with any of the points raised, please provide adequate justification in your letter.
2. A marked-up version of the manuscript that highlights changes made in response to the reviewers' comments in order to aid the Editors and reviewers.
3. A 'clean' (non-highlighted) version of the manuscript.

POST-ACCEPTANCE

*Nutrition & Diabetes* is an open access journal: authors pay an article processing charge (APC) for their accepted articles to be open access online and freely accessible, immediately upon publication, under a Creative Commons license.

Visit our [open research site](http://www.nature.com) for further information about licenses, APCs, and our free OA funding support service:

- [About Creative Commons licensing](http://www.nature.com)
- [Creative Commons license options and article processing charges (APCs) for Nutrition & Diabetes](http://www.nature.com)
- [APC payment FAQs](http://www.nature.com)
- [Help in identifying funding for APCs](http://www.nature.com)
- [APC waiver policy](http://www.nature.com)
- [Compliance with funding body requirements](http://www.nature.com)

Once a manuscript is accepted the corresponding author must complete an [Article Processing Charge (APC) payment form](http://www.nature.com) and an [open access License to Publish (LTP) form](http://www.nature.com) on behalf of all authors, and return these to the editorial office. Forms will be provided upon acceptance of the article. Failure to promptly return forms will result in delay of publication.

Government employees from the [United States](http://www.nature.com) and [UK](http://www.nature.com) are required to sign and submit the relevant government open access license to publish form. Please note with regards to payment that usual credit terms are 30 days from receipt of invoice. Failure to pay your invoice within the stated credit term may result in such penalties as restrictions on your ability to publish with Nature Publishing Group or Nutrition & Diabetes in the future, involvement of a third Party debt collection agency and legal proceedings.

**Manuscript deposition and self-archiving**

To facilitate self-archiving NPG deposits open access articles in PubMed Central and Europe PubMed Central on publication. Authors are also permitted to post the final, published PDF of their article on a website, institutional repository or other free public server, immediately on publication. Learn more about [self-archiving and deposition of papers published OA](http://www.nature.com).

**Proofs**

The corresponding author will receive an e-mail containing a URL linking to the proofing site. Proof corrections must be returned within 48 hours of receipt. Failure to do so may result in delayed publication. Extensive corrections cannot be made at this stage.
COSTS

*Nutrition & Diabetes* levies the following Article-Processing Charges (APC) per article accepted for publication. A payment form will need to be completed and returned alongside the License to Publish form. Failure to promptly return these forms will result in delay of publication.

With regards to payment, usual credit terms are 30 days from receipt of invoice. Failure to pay your invoice within the stated credit term may result in restrictions on your ability to publish with Nature Publishing Group or *Nutrition & Diabetes* in the future, involvement of a third party debt collection agency and legal proceedings.

<table>
<thead>
<tr>
<th></th>
<th>UK &amp; RoW</th>
<th>US</th>
<th>Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Article / Review Article / Technical Reports</td>
<td>£2,600</td>
<td>$3,500</td>
<td>€2,800</td>
</tr>
<tr>
<td>Brief Communication</td>
<td>£1,300</td>
<td>$2,000</td>
<td>€1,500</td>
</tr>
<tr>
<td>Correspondence</td>
<td>£800</td>
<td>$1,100</td>
<td>€900</td>
</tr>
</tbody>
</table>

(VAT or local taxes will be added where applicable)

Fee Waiver Policy

We offer APC waivers to authors from HINARI countries. Discretionary APC waivers will be considered on a case-by-case basis and may be granted in cases of financial need. All applications for APC waivers should be made prior to, or at the point of, manuscript submission; requests made during the review process or after acceptance will not be considered. To request a waiver, please contact us at openaccess@nature.com.

Open access funding

Visit Nature Publishing Group’s open access funding page for information about research funders and institutions that provide funding for open access.

NPG also offers an APC support service to make it easier for NPG authors to discover and apply for open access funding. For advice on what funding is available to you and help in approaching funders and institutions, please contact us at openaccess@nature.com.

For more information about NPG’s open access publishing options and policies, please see our open access homepage.

EDITORIAL POLICIES

**Duplicate Publication**

Papers must be original and not published or submitted for publication elsewhere. This rule also applies to non-English language publications. NPG allows and encourages prior publication on recognized community preprint servers for review by other scientists before formal submission to a journal. The details of the preprint server concerned and any accession numbers should be included in the cover letter accompanying manuscript submission. This policy does not extend to preprints available to the media or that are otherwise publicized outside the scientific community before or during the submission and consideration process.

**Permissions**

If a table or figure has been published before, the authors must obtain written permission to reproduce the material in both print and electronic formats from the copyright owner and submit it with the manuscript. This follows for quotes, illustrations and other materials taken from previously published works not in the public domain. The original source should be cited in the figure caption or table footnote. Colour figures can be reproduced if necessary, but the authors will be expected to contribute towards the cost of publication. A quote will be supplied upon acceptance of your paper.

**Clinical Trials**

As defined by the International Committee of Medical Journal Editors (ICMJE), a clinical trial is any research project that prospectively assigns human subjects to intervention and comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. A medical intervention is any intervention used to modify a health outcome and includes but is not limited to drugs, surgical procedures, devices, behavioural treatments, and process-of-care changes. A trial must have at least one prospectively assigned concurrent control or comparison group in order to trigger the requirement for registration. Nonrandomized trials are not exempt from the registration requirement if they meet the above criteria.

When reporting experiments on human subjects, please indicate whether the procedures were in accordance with the ethical standards of the responsible committee on human experimentation (institutional or regional) or with the Helsinki Declaration of 1975 (as revised in 1983). Include Institutional Review Board or Animal Care and Use Committee approvals.

All clinical trials must be registered in a public registry prior to submission. The journal follows the trials registration policy of the ICMJE (www.icmje.org) and considers only trials that have been appropriately registered before submission, regardless of when the trial closed to enrolment. Acceptable registries must meet the following ICMJE requirements:
Further information can be found at www.consort-statement.org. Trials and submissions must be accompanied by a completed CONSORT statement, (CONsolidated Standards Of Reporting Randomised Controlled Trials (RCTs) must adhere to the CONSORT during the submission process.

The trial registry number for eligible papers will be collected during the submission process.

Randomised Controlled Trials (RCTs) must adhere to the CONSORT statement, (CONsolidated Standards Of Reporting Trials) and submissions must be accompanied by a completed CONSORT checklist (uploaded as a related manuscript file). Further information can be found at www.consort-statement.org.

Nature Publishing Group endorses the toolkits and guidelines produced by the Committee on Publication Ethics (COPE): http://publicationethics.org/

Conflict of Interest

In the interests of transparency and to help readers form their own judgments of potential bias, authors must declare whether or not there are any competing financial interests in relation to the work described. This information must be included in their cover letter and on the title page of their manuscript. In cases where the authors declare a competing financial interest, a statement to that effect is published as part of the article. If no such conflict exists, the statement will simply read that the authors have nothing to disclose.

For the purposes of this statement, competing interests are defined as those of a financial nature that, through their potential influence on behaviour or content, or from perception of such potential influences, could undermine the objectivity, integrity or perceived value of a publication. They can include any of the following:

- Funding: Research support (including salaries, equipment, supplies, reimbursement for attending symposia, and other expenses) by organizations that may gain or lose financially through this publication. The role of the funding body in the design of the study, collection and analysis of data and decision to publish should be stated.
- Employment: Recent (while engaged in the research project), present or anticipated employment by any organization that may gain or lose financially through this publication.
- Personal financial interests: Stocks or shares in companies that may gain or lose financially through publication; consultation fees or other forms of remuneration from organizations that may gain or lose financially; patents or patent applications whose value may be affected by publication.

It is difficult to specify a threshold at which a financial interest becomes significant, but note that many US universities require faculty members to disclose interests exceeding $10,000 or 5% equity in a company. Any such figure is arbitrary, so we offer as one possible practical alternative guideline: “Declare all interests that could embarrass you were they to become publicly known after your work was published.” We do not consider diversified mutual funds or investment trusts to constitute a competing financial interest.

The statement must contain an explicit and unambiguous statement describing any potential conflict of interest, or lack thereof, for any of the authors as it relates to the subject of the report. Examples include “Dr. Smith receives compensation as a consultant for XYZ Company,” “Dr. Jones and Dr. Smith have financial holdings in ABC Company,” or “Dr. Jones owns a patent on the diagnostic device described in this report.” These statements acknowledging or denying conflicts of interest must be included in the manuscript under the heading Conflict of Interest. The Conflict of Interest disclosure appears in the cover letter, in the manuscript submission process and before the References section in the manuscript.

Following the Conflict of Interest heading, there must be a listing for each author, detailing the professional services relevant to the submission. Neither the precise amount received from each entity nor the aggregate income from these sources needs to be provided. Professional services include any activities for which the individual is, has been, or will be compensated with cash, royalties, fees, stock or stock options in exchange for work performed, advice or counsel provided, or for other services related to the author’s professional knowledge and skills. This would include, but not necessarily be limited to, the identification of organizations from which the author received contracts or in which he or she holds an equity stake if professional services were provided in conjunction with the transaction.

Examples of declarations are:

- **Conflict of interest.**
  The authors declare no conflict of interest.
- **Conflict of interest.**
  Dr. Caron’s work has been funded by the NIH. He has received compensation as a member of the scientific advisory board of Acadia Pharmaceutical and owns stock in the company. He also has consulted for Lundbeck and received compensation. Dr. Rothman and Dr. Jensen declare no potential conflict of interest.

Authorship

Requirements for all categories of articles should conform to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals,” developed by the ICMJE (www.icmje.org).

Each author must have contributed sufficiently to the intellectual content of the submission. The corresponding author should list all authors and their contributions to the work. Any changes to the author list after submission, such as a change in the order of the authors, or the deletion or addition of authors, must be approved by a signed letter from every author. The corresponding author must confirm that he or she has had full access to the data in the study and final responsibility for the decision to submit for publication. To qualify as a contributing author, one must meet all of the following criteria:
1) Conceived and/or designed the work that led to the submission, acquired data, and/or played an important role in interpreting the results.
2) Drafted or revised the manuscript.
3) Approved the final version.

Contributions by individuals who made direct contributions to the work but do not meet all of the above criteria should be noted in the Acknowledgments section of the manuscript. Medical writers and industry employees can be contributors. Their roles, affiliations, and potential conflicts of interest should be included in the author list or noted in the Acknowledgments and/or Contributors section concurrent with their contribution to the work submitted. Signed statements from any medical writers or editors declaring that they have given permission to be named as an author, as a contributor, or in the Acknowledgments section is also required. Failure to acknowledge these contributors can be considered inappropriate, which conflicts with the journal’s editorial policy.

Reproducibility

As of March 2015, *Nutrition and Diabetes* requires authors of papers that are sent for external review to include in their manuscripts relevant details about several elements of experimental and analytical design. This initiative aims to improve the transparency of reporting and the reproducibility of published results, focusing on elements of methodological information that are frequently poorly reported. Authors being asked to resubmit a manuscript will be asked to confirm that these elements are included by filling out a checklist that will be made available to the editor and reviewers.

Correspondence with the Journal

One author is designated the contact author for matters arising from the manuscript (materials requests, technical comments and so on). It is this author’s responsibility to inform all co-authors of matters arising and to ensure such matters are dealt with promptly. Before submission, the corresponding author ensures that all authors are included in the author list, in order agreed upon by all authors, and are aware that the manuscript was submitted. After acceptance for publication, proofs are e-mailed to this corresponding author who should circulate the proof to all co-authors and coordinate corrections among them.

Plagiarism and Fabrication

CrossCheck is a multi-publisher initiative to screen published and submitted content for originality. NPG Journals use CrossCheck to detect instances of overlapping and similar text in submitted manuscripts. To find out more about CrossCheck visit [www.crossref.org/crosscheck.html](http://www.crossref.org/crosscheck.html).

Plagiarism is when an author attempts to pass off someone else’s work as his or her own. Duplicate publication, sometimes called self-plagiarism, occurs when an author reuses substantial parts of his or her own published work without providing the appropriate references. Minor plagiarism without dishonest intent is relatively frequent, for example, when an author reuses parts of an introduction from an earlier paper.

If plagiarism is found, the journal will contact the author’s institute and funding agencies. The paper containing the plagiarism will be marked on each page of the PDF and depending on the extent of the plagiarism, a published article may also be formally retracted.

Image Integrity and Standards

Images submitted with a manuscript for review should be minimally processed (for instance, to add arrows to a micrograph). Authors should retain their unprocessed data and metadata files, as editors may request them to aid in manuscript evaluation. If unprocessed data is unavailable, manuscript evaluation may be stalled until the issue is resolved.

A certain degree of image processing is acceptable for publication, but the final image must correctly represent the original data and conform to community standards. The guidelines below will aid in accurate data presentation at the image processing level:

- Authors should list all image acquisition tools and image processing software packages used. Authors should document key image-gathering settings and processing manipulations in the Methods section.
- Images gathered at different times or from different locations should not be combined into a single image, unless it is stated that the resultant image is a product of time-averaged data or a time-lapse sequence. If juxtaposing images is essential, the borders should be clearly demarcated in the figure and described in the legend.
- Touch-up tools, such as cloning and healing tools in Photoshop, or any feature that deliberately obscures manipulations, is to be avoided.
- Processing (such as changing brightness and contrast) is appropriate only when it is applied equally across the entire image and is applied equally to controls. Contrast should not be adjusted so that data disappear. Excessive manipulations, such as processing to emphasize one region in the image at the expense of others (for example, through the use of a biased choice of threshold settings), is inappropriate, as is emphasizing experimental data relative to the control.

For *gels and blots*, positive and negative controls, as well as molecular size markers, should be included on each gel and blot – either in the main figure or an expanded data supplementary figure. The display of cropped gels and blots in the main paper is encouraged if it improves the clarity and conciseness of the presentation. In such cases, the cropping must be mentioned in the figure legend.

- Vertically sliced gels that juxtapose lanes that were not contiguous in the experiment must have a clear separation or a black line delineating the boundary between the gels.
- Cropped gels in the paper must retain important bands.
- Cropped blots in the body of the paper should retain at least six band widths above and below the band.
- High-contrast gels and blots are discouraged, as overexposure may mask additional bands. Authors should strive for exposures with gray backgrounds. Immunoblots should be surrounded by a black line to indicate the borders of the blot, if the background is faint.
- For quantitative comparisons, appropriate reagents, controls and imaging methods with linear signal ranges should be used.

Microscopy adjustments should be applied to the entire image. Threshold manipulation, expansion or contraction of signal ranges and the altering of high signals should be avoided. If ‘pseudo-
colouring’ and nonlinear adjustment (for example ‘gamma changes’) are used, this must be disclosed. Adjustments of individual colour channels are sometimes necessary on ‘merged’ images, but this should be noted in the figure legend. We encourage inclusion of the following with the final revised version of the manuscript for publication:

- In the Methods section, specify the type of equipment (microscopes/objective lenses, cameras, detectors, filter model and batch number) and acquisition software used. Although we appreciate that there is some variation between instruments, equipment settings for critical measurements should also be listed.
- The display lookup table (LUT) and the quantitative map between the LUT and the bitmap should be provided, especially when rainbow pseudo-colour is used. It should be stated if the LUT is linear and covers the full range of the data.
- Processing software should be named and manipulations indicated (such as type of deconvolution, three-dimensional reconstructions, surface and volume rendering, ‘gamma changes’, filtering, thresholding and projection).
- Authors should state the measured resolution at which an image was acquired and any downstream processing or averaging that enhances the resolution of the image.

Availability of Data and Materials

An inherent principle of publication is that others should be able to replicate and build upon the authors’ published claims. Therefore, a condition of publication is that authors are required to make materials, data, and associated protocols available in a publicly accessible database. Where one does not exist, the information must be made available to referees at submission and to readers promptly upon request. Any restrictions on material availability or other relevant information must be disclosed in the manuscript’s Methods section and should include details of how materials and information may be obtained.

Sequences, Structures and “Oomics”

Papers reporting protein or DNA sequences and molecular structures will not be accepted without an accession number to Genbank/EMBL/DDBJ, SWISS-PROT, ProteinDataBank, or other publicly available database in general use in the field that gives free access to researchers from the date of publication.

Authors of papers describing structures of biological macromolecules must provide experimental data upon the request of Editor if they are not already freely accessible in a publicly available database such as ProteinDataBank, Biological Magnetic Resonance Databank, or Nucleic Acid Database.

Human and Other Animal Experiments

For primary research manuscripts reporting experiments on live vertebrates and/or higher invertebrates, the corresponding author must confirm that all experiments were performed in accordance with relevant guidelines and regulations. All manuscripts reporting animal research must be written up in accordance with the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines – see http://www.nc3rs.org/ARRIVE.

The manuscript must include in the Supplementary Information (methods) section (or, if brief, within of the print/online article at an appropriate place), a statement identifying the institutional and/or licensing committee approving the experiments, including any relevant details regarding animal welfare, patient anonymity, drug side effects and informed consent. For experiments involving human subjects, authors must identify the committee approving the experiments, and include with their submission a statement confirming that informed consent was obtained from all subjects.

Biosecurity Policy

The Editor may seek advice about submitted papers not only from technical reviewers but also on any aspect of a paper that raises concerns. These may include, for example, ethical issues or issues of data or materials access. Occasionally, concerns may also relate to the implications to society of publishing a paper, including threats to security. In such circumstances, advice will usually be sought simultaneously with the technical peer-review process. As in all publishing decisions, the ultimate decision whether to publish is the responsibility of the editor of the journal concerned.

Peer Review

Manuscripts sent out for peer review are evaluated by at least one independent reviewer (often two or more). Authors are welcome to suggest independent reviewers to evaluate their manuscript, as well as request individuals or laboratories. All recommendations are considered, but it is at the Editor’s discretion their choice of reviewers. To expedite the review process, only papers that seem most likely to meet editorial criteria are sent for external review. Papers judged by the editors to be of insufficient general interest or otherwise inappropriate are rejected promptly without external review. The editors then make a decision based on the reviewers’ evaluations:

- **Accept**, with or without editorial revisions.
- **Revise**, with the author addressing concerns raised by the reviewers before a final decision is reached.
- **Reject**, but indicate to the authors that further work might justify a resubmission.
- **Reject outright**, typically on grounds of specialist interest, lack of novelty, insufficient conceptual advance or major technical and/or interpretational problems.

Anonymity and Confidentiality

All details about submitted manuscripts are kept confidential and no comments are issued to outside parties or organizations about manuscripts under consideration or if they are rejected. Editors are restricted to making public comments on a published article’s content and their evaluation.

We do not release reviewers’ identities to authors, except when reviewers specifically ask to be identified.

We ask reviewers not to identify themselves to authors without the editor’s knowledge. If they wish to reveal their identities while the manuscript is under consideration, this should be done via the editor; if this is not practicable, we ask authors to inform the editor as soon as possible after the reviewer has revealed their identity. We deplore any attempt by authors to confront reviewers or try to determine their identities. Our own policy is to neither confirm nor
deny any speculation about reviewers’ identities, and we encourage reviewers to adopt a similar policy.

Upon accepting an invitation to evaluate a manuscript, reviewers must keep the manuscript and associated data confidential, and not redistribute them without the journal’s permission. If a reviewer asks a colleague to assist in assessing a manuscript, confidentiality must be ensured and their names must be provided to the journal with the final report.

Selecting Peer Reviewers

Reviewer selection is critical to the publication process, and we base our choice on many factors, based on expertise, reputation, and specific recommendations. A reviewer may decline the invitation to evaluate a manuscript where there is a perceived conflict of interest (financial or otherwise).

Communication with the Media

Material submitted must not be discussed with the media. We reserve the right to halt the consideration or publication of a paper if this condition is broken. If a paper is particularly newsworthy, the press release will be sent to our list of journalists in advance of publication with an embargo that forbids any coverage of the manuscript, or the findings of the manuscript, until the time and date clearly stated. Authors whose papers are scheduled for publication may also arrange their own publicity (for instance through their institution’s press offices), but they must strictly adhere to our press embargo and are advised to coordinate their own publicity with our press office.

Communication Between Scientists

We do not wish to hinder communication between scientists. We ask you to communicate with other researchers as much as you wish, whether on a recognized community preprint server, by discussion at scientific meetings or by online collaborative sites such as wikis, but we do not encourage premature publication by discussion with the press (beyond a formal presentation, if at a conference).

Pre- and Post-Submissions

Authors are welcome to post pre-submission versions or the original submitted version of the manuscript on a personal blog, a collaborative wiki or a recognized pre-print server (such as ArXiv) at any time (but not subsequent pre-accept versions that evolve due to the editorial process).

For subscribed content, the accepted version of the manuscript, following the review process, may only be posted 6 months after the paper is published in an NPG journal. A publication reference and URL to the published version on the journal website must be provided on the first page of the pre-print. The published version — copyedited and in the individual NPG journal format — may not be posted on any website or preprint server.

For open access content published under a creative commons license, authors can replace the submitted version with the final published version at publication as long as a publication reference and URL to the published version on the journal website are provided.

Correction and Retraction Process

We recognize our responsibility to correct errors. Content published online is final and cannot be amended. Please note the following policy for making corrections to peer-reviewed content.

- **Correction.** Notification of an important error made by the journal or by the author that affects the publication record or the scientific integrity of the paper, or the reputation of the authors, or of the journal.
- **Retraction.** Notification of invalid results. All co-authors must sign a retraction specifying the error and stating briefly how the conclusions are affected.

Decisions about corrections are made by the Editor (sometimes with peer-reviewers’ advice) and this sometimes involves author consultation. Requests to make corrections that do not affect the paper in a significant way or impair the reader’s understanding of the contribution (a spelling mistake or grammatical error, for example) are not considered.

In cases where co-authors disagree about a correction, the editors will take advice from independent peer-reviewers and impose the appropriate correction, noting the dissenting author(s) in the text of the published version.

FURTHER INFORMATION

For inquiries related to submission requirements, please contact the editorial office. For inquiries related to advertising, subscriptions, permissions, papers in production or publishing a supplement, please contact the publisher’s office.